Company
Mayne Pharma Group Limited
Headquarters: Salisbury South, SA, Australia
CEO: Mr. Scott Anthony Richards
Market Cap
A$390.0 Million
AUD as of July 1, 2024
US$259.8 Million
Mayne Pharma Group Limited Categories
Australia Healthcare Drug Manufacturers—GeneralAustralia Healthcare Australia Drug Manufacturers—General
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—General
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
| AbbVie | $295.34 B |
| AstraZeneca | $236.45 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Detailed Description
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, the United States, Asia, and internationally. The company operates through four segments: Generic Products, Specialty Products, Metrics Contract Services, and Mayne Pharma International. It provides oral drug delivery systems; and contract pharmaceutical development, manufacturing, and analytical services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Stocks & Indices
Mayne Pharma Group Limited has the following listings and related stock indices.
Stock: ASX: MYX wb_incandescent